Drug · DIN 02520125
HYPERHEP B
NEONATAL, PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 16, 2022; first marketed August 16, 2022.
- Drug Identification Number (DIN)
- 02520125
- Company (DIN owner)
- Grifols Therapeutics LlcClayton, North Carolina, United States
- Schedule
- Schedule d
- Dosage form
- Solution
- Route
- Intramuscular
- Therapeutic class (ATC)
- Hepatitis b immunoglobulin J06BB04
- Class
- Human
- Record last updated
- August 24, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| HEPATITIS B IMMUNOGLOBULIN (HUMAN) | 110 UNIT | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 8, 2021: NOC 26653Supplement to a New Drug Submission (SNDS) · Changes to the manufacturing process, to the description of the drug product and new presentation
Other DINs named HYPERHEP B
- DIN 02520001 · Marketed
- DIN 02520133 · Approved